Pathogenese und Therapie der nicht arteriitischen anterioren ischämischen Optikusneuropathie

Zusammenfassung

Die nicht arteriitische anteriore ischämische Optikusneuropathie (NAION) ist eine akute Sehnervendegeneration, deren Pathogenese in großen Teilen unerforscht ist. Für sie existiert derzeit keine allgemein akzeptierte Behandlungsmöglichkeit. Die Etablierung von AION-Tiermodellen sowie die Ergebnisse größerer epidemiologischer Studien ermöglichten es in den vergangenen Jahren, ein besseres Verständnis der Pathophysiologie und möglicher Einflussfaktoren zu gewinnen. Basierend auf diesen Erkenntnissen testeten und testen klinische und tierexperimentelle Studien eine große Bandbreite möglicher Behandlungsansätze. Unabhängig von ihrem jeweiligen Ergebnis können diese Untersuchungen unser Verständnis der NAION erheblich erweitern und auch für andere Sehnervendegenerationen von großer Bedeutung sein.

Abstract

Non-arteritic anterior ischemic optic neuropathy (NAION) is an acute neurodegenerative disease with a largely elusive early pathogenesis and no specific therapy. Recent data from animal models of the disease as well as from epidemiological studies have provided new insights into the disease mechanism of NAION. On the basis of this new knowledge, a broad variety of therapeutic approaches is currently being evaluated in animal and clinical studies. This review aims to provide an overview of the pathogenesis as well as neuroprotective therapeutic concepts of recent and currently running studies.

Schlüsselwörter

nicht arteriitische anteriore ischämische Optikusneuropathie - Steroide - Caspase-Inhibition

Key words

non-arteritic anterior ischemic optic neuropathy - steroids - caspase-inhibition

• Literatur

• 1 Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol 1994; 14: 38-44
• 2 Cestari DM, Gaier ED, Bouzika P. et al. Demographic, systemic, and ocular factors associated with nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2016; 123: 2446-2455
• 3 Clinical Trial Disclosure Group, Pfizer Inc.. The Detection and Epidemiology of NAION in a Commercially Insured Population in the United States. Pfizer; 2011. Im Internet: https://clinicaltrials.gov/ct2/show/NCT01260324 Stand: 18.07.2019
• 4 Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology 2008; 115: 298-305.e2
• 5 Luneau K, Newman NJ, Biousse V. Ischemic optic neuropathies. Neurologist 2008; 14: 341-354
• 6 Scherer RW, Feldon SE, Levin L. et al. Visual fields at follow-up in the Ischemic Optic Neuropathy Decompression Trial: evaluation of change in pattern defect and severity over time. Ophthalmology 2008; 115: 1809-1817
• 7 Newman NJ, Scherer R, Langenberg P. et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 2002; 134: 317-328
• 8 Hayreh SS. Anterior ischaemic optic neuropathy. II. Fundus on ophthalmoscopy and fluorescein angiography. Br J Ophthalmol 1974; 58: 964-980
• 9 Miller GR, Smith JL. Ischemic optic neuropathy. Am J Ophthalmol 1966; 62: 103-115
• 10 Kernstock C, Beisse F, Wiethoff S. et al. Assessment of functional and morphometric endpoints in patients with non-arteritic anterior ischemic optic neuropathy (NAION). Graefes Arch Clin Exp Ophthalmol 2014; 252: 515-521
• 11 Berry S, Lin WV, Sadaka A, Lee AG. Nonarteritic anterior ischemic optic neuropathy: cause, effect, and management. Eye Brain 2017; 9: 23-28
• 12 Roth S, Moss HE. Update on perioperative ischemic optic neuropathy associated with non-ophthalmic surgery. Front Neurol 2018; 9: 557
• 13 Sun MH, Lee CY, Liao YJ. et al. Nonarteritic anterior ischaemic optic neuropathy and its association with obstructive sleep apnoea: a health insurance database study. Acta Ophthalmol (Copenh) 2019; 97: e64
• 14 Yang HK, Park SJ, Byun SJ. et al. Obstructive sleep apnoea and increased risk of non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol 2018;
• 15 Kuhli-Hattenbach C, Scharrer I, Lüchtenberg M. et al. [Thrombophilic disorders associated with non-arteritic anterior ischaemic optic neuropathy in patients < 60 years of age]. Klin Monatsbl Augenheilkd 2008; 225: 1065-1069
• 16 Liu B, Zhu L, Zhong J. et al. The association between phosphodiesterase type 5 inhibitor use and risk of non-arteritic anterior ischemic optic neuropathy: a systematic review and meta-analysis. Sex Med 2018; 6: 185-192
• 17 Bernstein SL, Guo Y, Kelman SE. et al. Functional and cellular responses in a novel rodent model of anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci 2003; 44: 4153-4162
• 18 Danylkova NO, Pomeranz HD, Alcala SR. et al. Histological and morphometric evaluation of transient retinal and optic nerve ischemia in rat. Brain Res 2006; 1096: 20-29
• 19 Chen CS, Johnson MA, Flower RA. et al. A primate model of nonarteritic anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci 2008; 49: 2985-2992
• 20 Bernstein SL, Johnson MA, Miller NR. Nonarteritic anterior ischemic optic neuropathy (NAION) and its experimental models. Prog Retin Eye Res 2011; 30: 167-187
• 21 Huang TL, Wen YT, Chang CH. et al. Early methylprednisolone treatment can stabilize the blood-optic nerve barrier in a rat model of anterior ischemic optic neuropathy (rAION). Invest Ophthalmol Vis Sci 2017; 58: 1628-1636
• 22 Slater BJ, Vilson FL, Guo Y. et al. Optic nerve inflammation and demyelination in a rodent model of nonarteritic anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci 2013; 54: 7952-7961
• 23 Zhang C, Guo Y, Miller NR. et al. Optic nerve infarction and post-ischemic inflammation in the rodent model of anterior ischemic optic neuropathy (rAION). Brain Res 2009; 1264: 67-75
• 24 Mehrabian Z, Guo Y, Weinreich D. et al. Oligodendrocyte death, neuroinflammation, and the effects of minocycline in a rodent model of nonarteritic anterior ischemic optic neuropathy (rNAION). Mol Vis 2017; 23: 963-976
• 25 Knox DL, Kerrison JB, Green WR. Histopathologic studies of ischemic optic neuropathy. Trans Am Ophthalmol Soc 2000; 98: 203-220
• 26 Ransohoff RM. A polarizing question: do M1 and M2 microglia exist?. Nat Neurosci 2016; 19: 987-991
• 27 Wang J, Xing H, Wan L. et al. Treatment targets for M2 microglia polarization in ischemic stroke. Biomed Pharmacother 2018; 105: 518-525
• 28 Parsa CF, Hoyt WF. Nonarteritic anterior ischemic optic neuropathy (NAION): a misnomer. Rearranging pieces of a puzzle to reveal a nonischemic papillopathy caused by vitreous separation. Ophthalmology 2015; 122: 439-442
• 29 Schmidt D, Ness T. [Ocular findings and differential diagnoses in giant cell arteritis (Arteriitis cranialis)]. Z Rheumatol 2009; 68: 117-123
• 30 Patel HR, Margo CE. Pathology of ischemic optic neuropathy. Arch Pathol Lab Med 2017; 141: 162-166
• 31 [Anonymous] Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group. JAMA 1995; 273: 625-632
• 32 [Anonymous] Ischemic Optic Neuropathy Decompression Trial: twenty-four-month update. Arch Ophthalmol 2000; 118: 793-798
• 33 Wilhelm B, Lüdtke H, Wilhelm H. et al. Efficacy and tolerability of 0.2 % brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. Graefes Arch Clin Exp Ophthalmol 2006; 244: 551-558
• 34 Fazzone HE, Kupersmith MJ, Leibmann J. Does topical brimonidine tartrate help NAION?. Br J Ophthalmol 2003; 87: 1193-1194
• 35 Stunkel L, Van Stavern GP. Steroid treatment of optic neuropathies. Asia Pac J Ophthalmol (Phila) 2018; 7: 218-228
• 36 Hayreh SS, Zimmerman MB. Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1029-1046
• 37 Pakravan M, Esfandiari H, Hassanpour K. et al. The effect of combined systemic erythropoietin and steroid on non-arteritic anterior ischemic optic neuropathy: a prospective study. Curr Eye Res 2017; 42: 1079-1084
• 38 Saxena R, Singh D, Sharma M. et al. Steroids versus no steroids in nonarteritic anterior ischemic optic neuropathy: a randomized controlled trial. Ophthalmology 2018; 125: 1623-1627
• 39 Prokosch V, Thanos S. Visual outcome of patients following NAION after treatment with adjunctive fluocortolone. Restor Neurol Neurosci 2014; 32: 381-389
• 40 Rebolleda G, Pérez-López M, Casas-LLera P. et al. Visual and anatomical outcomes of non-arteritic anterior ischemic optic neuropathy with high-dose systemic corticosteroids. Graefes Arch Clin Exp Ophthalmol 2013; 251: 255-260
• 41 Pakravan M, Sanjari N, Esfandiari H. et al. The effect of high-dose steroids, and normobaric oxygen therapy, on recent onset non-arteritic anterior ischemic optic neuropathy: a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2016; 254: 2043-2048
• 42 Moster ML, Sergott RC, Leiby BE. Dalfampridine treatment in nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 2017; 37: 348
• 43 Micieli JA, Lam C, Najem K. et al. Aqueous humor cytokines in patients with acute nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 2017; 177: 175-181
• 44 Rootman DB, Gill HS, Margolin EA. Intravitreal bevacizumab for the treatment of nonarteritic anterior ischemic optic neuropathy: a prospective trial. Eye (Lond) 2013; 27: 538-544
• 45 Huang TL, Chang CH, Chang SW. et al. Efficacy of intravitreal injections of antivascular endothelial growth factor agents in a rat model of anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci 2015; 56: 2290-2296
• 46 Arnold AC, Levin LA. Treatment of ischemic optic neuropathy. Semin Ophthalmol 2002; 17: 39-46
• 47 Arnold AC, Hepler RS, Lieber M, Alexander JM. Hyperbaric oxygen therapy for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1996; 122: 535-541
• 48 Johnson LN, Guy ME, Krohel GB. et al. Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2000; 107: 521-526
• 49 Johnson LN, Gould TJ, Krohel GB. Effect of levodopa and carbidopa on recovery of visual function in patients with nonarteritic anterior ischemic optic neuropathy of longer than six monthsʼ duration. Am J Ophthalmol 1996; 121: 77-83
• 50 Lyttle DP, Johnson LN, Margolin EA. et al. Levodopa as a possible treatment of visual loss in nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2016; 254: 757-764
• 51 Simsek T, Eryilmaz T, Acaroglu G. Efficacy of levodopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy. Int J Clin Pract 2005; 59: 287-290
• 52 Mathews MK, Guo Y, Langenberg P. et al. Ciliary neurotrophic factor (CNTF)-mediated ganglion cell survival in a rodent model of non-arteritic anterior ischaemic optic neuropathy (NAION). Br J Ophthalmol 2015; 99: 133-137
• 53 Thomas CN, Berry M, Logan A. et al. Caspases in retinal ganglion cell death and axon regeneration. Cell Death Discov 2017; 3: 17032
• 54 Secades JJ, Alvarez-Sabín J, Castillo J. et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis 2016; 25: 1984-1996
• 55 Parisi V, Oddone F, Ziccardi L. et al. Citicoline and retinal ganglion cells: effects on morphology and function. Curr Neuropharmacol 2018; 16: 919-932
• 56 Chang CH, Huang TL, Huang SP. et al. Neuroprotective effects of recombinant human granulocyte colony-stimulating factor (G-CSF) in a rat model of anterior ischemic optic neuropathy (rAION). Exp Eye Res 2014; 118: 109-116
• 57 Wen YT, Huang TL, Huang SP. et al. Early applications of granulocyte colony-stimulating factor (G-CSF) can stabilize the blood-optic-nerve barrier and ameliorate inflammation in a rat model of anterior ischemic optic neuropathy (rAION). Dis Model Mech 2016; 9: 1193-1202
• 58 Sasaki A. Microglia and brain macrophages: an update. Neuropathology 2017; 37: 452-464
• 59 Kapupara K, Wen YT, Tsai RK. et al. Soluble P-selectin promotes retinal ganglion cell survival through activation of Nrf2 signaling after ischemia injury. Cell Death Dis 2017; 8: e3172
• 60 Georgiou T, Wen YT, Chang CH. et al. Neuroprotective effects of omega-3 polyunsaturated fatty acids in a rat model of anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci 2017; 58: 1603-1611